Medical technology company RaySearch Laboratories AB (RaySearch) (STO:RAYB) announced on Friday that Proton Therapy Center Czech (Prague PTC) has selected RayStation as its sole treatment planning system.
The company said this is its first order from Czechia.
This order has a total order value of SEK6,2m and the majority of the revenues will be recognised within the second quarter of 2019.
Prague PTC was established in 2012 and has since then been treating patients with a wide scale of cancer diagnoses such as prostate, lung, breast, head-and-neck and brain, using proton therapy.
RaySearch develops innovative software solutions to improve cancer care. The company markets the RayStation treatment planning system and RayCare, the next-generation oncology information system, worldwide.
(EUR1.00=SEK10.75)
Acerus and Aytu Bioscience to Co-promote Natesto in the United States
Amgen reports financial results for Q2 2019
Pfizer to integrate Upjohn with Mylan to establish new global pharmaceutical company
Neurocrine Biosciences reports half-year ended 30 June 2019 financial results
Thermo Fisher Scientific reports financial results for Q2 2019
Veloxis Pharmaceuticals revises 2019 outlook
NANOBIOTIX collects revenues of EUR31.9,000 for Q2 2019
Seattle Genetics incurs net loss of USD79.2m in Q2 2019
Baxter's board announces USD0.22 per share dividend pay order
Johnson & Johnson declares dividend of USD0.95 per share for Q3 2019
Sun Pharma Launches Ezallor Sprinkle in the US for People Who Have Difficulty Swallowing
PanTheryx Aims to End Diarrheal Disease in Cambodia
CCA Industries Inc swings to income of USD349,320 for Q2 2019
Oncimmune Holdings signs commercial collaboration with R-Pharm JSC